Financial
FY2025 revenue $2.71bn (+30.7%); operating margin 17.5%; net income $247.1m.
Cash $716.1m; debt $949.2m.
Insulet
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Strong
Customer rating
No reviews yet
Financial health
Band: StrongListed: PODD
FY2025 revenue $2.71bn (+30.7%); operating margin 17.5%; net income $247.1m.
Cash $716.1m; debt $949.2m.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | US$2.7bn | +30.7% | US$473.8m | US$247.1m | Insulet |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Jul 2026: A US securities class action was filed against Insulet alleging it failed to disclose manufacturing control weaknesses ahead of its 2026 Omnipod pod corrections; the claims are unproven. No company response reported in the sources reviewed.
Cyber & information governance
No data breaches, cyber incidents or regulator action involving Insulet found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
Mar 2026: Insulet corrected certain Omnipod 5 Pod lots after internal tubing tears could cause insulin under-delivery; FDA classed it Class I, with 29 serious injuries and no deaths reported. A further correction covering Omnipod 5, DASH and Eros Pods followed in May 2026.
Contract performance
No notable contract disputes, terminations or significant NHS/UK public sector contracts involving Insulet found in HSH's search of the last 24 months.
Competitors
No competitors linked yet.